Search

Your search keyword '"Dániel Szűcs"' showing total 24 results
Start Over Author "Dániel Szűcs"
24 results on '"Dániel Szűcs"'

1. Epidemiology and clinical features of SARS‐CoV‐2 infection in hospitalized children across four waves in Hungary: A retrospective, comparative study from March 2020 to December 2021

Author

Andrea T. Takács, Mátyás Bukva, Gabriella Gavallér, Katalin Kapus, Mária Rózsa, Boglárka Bán‐Gagyi, Mária Sinkó, Dániel Szűcs, Gabriella Terhes, and Csaba Bereczki

Subjects
children, COVID‐19, hospitalization wave, SARS‐CoV‐2 infection, Medicine
Abstract

Abstract Background and Aims From 2019 till the present, infections induced by the novel coronavirus and its mutations have posed a new challenge for healthcare. However, comparative studies on pediatric infections throughout waves are few. During four different pandemic waves, we intended to investigate the clinical and epidemiological characteristic of the pediatric population hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection. Methods Between March 2020 and December 2021, we performed our retrospective research on children infected with the SARS‐CoV‐2 virus at the University of Szeged. We analyzed the data of all patients who required hospitalization due to positive results of SARS‐CoV‐2 tests (Nucleic Acid Amplification Test or rapid antigen test). Data analysis included demographic data, medical history, clinical findings, length of hospitalization, and complications, using medical records. Results In this study, data from 358 coronavirus‐infected children were analyzed. The most affected age group was children over 1 month and under 1 year (30.2%). The highest number of cases was recorded in the fourth wave (53.6%). Fever (65.6%), cough (51.4%), nasal discharge (35.3%), nausea and vomiting (31.3%), and decreased oral intake (28.9%) were the most common symptoms. The most common complications were dehydration (50.5%), pneumonia (14.9%), and bronchitis/bronchiolitis (14.5%). Based on RR values, there are considerable differences in the prevalence of the symptoms and complications between the different age groups and waves. Cox proportional hazard model analyzes showed that fever and tachypnoea had a relevant effect on days to recovery. Conclusions We found trends similar to those previously published, overall statistics. The proportion of children requiring hospitalization varied from wave to wave, with the fourth wave affecting the Hungarian child population the most. Our findings suggest that hospitalization time is unrelated to age, but that certain symptoms (fever and tachypnoea) are associated with longer hospitalization. The onset of certain symptoms may differ by age group.

Published
2022
Full Text
View/download PDF

2. Adherence to the Porto Criteria Based on the Hungarian Nationwide Pediatric Inflammatory Bowel Disease Registry (HUPIR)

Author

Katalin E. Müller, Antal Dezsőfi, Áron Cseh, Dániel Szűcs, Noémi Vass, Éva Nemes, Orsolya Kadenczki, András Tárnok, Erzsébet Szakos, Ildikó Guthy, Márta Kovács, Anna Karoliny, Judit Czelecz, István Tokodi, Erika Tomsits, and Gábor Veres

Subjects
inflammatory bowel disease, children, diagnostic work up, Porto criteria, Crohn's disease, ulcerative colitis, Pediatrics, RJ1-570
Abstract

Objectives: According to the Porto criteria, upper endoscopy and ileocolonoscopy with histology for patients with pediatric inflammatory bowel disease (pIBD) are recommended with small bowel imaging (SBI). We aimed to evaluate the adherence to the Porto criteria and biopsy sampling practice and to evaluate the diagnostic yield of magnetic resonance enterography (MRE) first time in a nationwide pIBD inception cohort.Methods: Newly diagnosed pIBD cases (ages 0–18 years) are registered in the prospective, nationwide Hungarian Paediatric IBD Registry (HUPIR). We analyzed the diagnostic workup of patients recorded between the 1st of January 2007 and the 31st of December 2016.Results: Data for diagnostic workup was available in 1,523 cases. Forty percent of the cases had complied with the Porto criteria. Adherence to the Porto criteria increased significantly from 20 to 57% (p < 0.0001) between 2007 and 2016. The most frequent reason for the incomplete diagnostic work-up was the lack of small bowel imaging (59%). In 2007, 8% of cases had a biopsy from all segments, and this rate reached 51% by 2016 (p < 0.0001). We analyzed the diagnostic yield of MRE in 113 patients (10.1%), who did not have any characteristic lesion for Crohn's disease. The MRE was positive for the small bowel in 44 cases (39%).Conclusions: Adherence to the Porto criteria increased significantly during the 10-year period. This is the first study that reports multiple biopsy sampling as the less accepted recommendation. The diagnostic yield of MRE in patients without characteristic lesion for Crohn's disease is 39%.

Published
2021
Full Text
View/download PDF

3. Lepedékes tonsilla gyermekkorban. Hogyan csökkenthető az indokolatlan antibiotikumfelhasználás?

Author

Gabriella Terhes, Dániel Szűcs, and Andrea Takács

Subjects
medicine.medical_specialty, medicine.drug_class, business.industry, Antibiotics, Congenital cytomegalovirus infection, General Medicine, medicine.disease, medicine.disease_cause, Group A, Virus, Serology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Streptococcus pyogenes, medicine, Elevated transaminases, 030211 gastroenterology & hepatology, business, Exudative tonsillitis
Abstract

Absztrakt: Bevezetés: A lepedékkel, tüszőkkel fedett, gyulladt tonsilla gyakori elváltozásnak számít a gyermekgyógyászatban. A tünet hátterében az esetek nagyobb részében vírusfertőzés (Epstein–Barr-vírus [EBV], cytomegalovirus [CMV], influenza, parainfluenza, adenovírus) áll; csak kisebb arányban baktériumok, melyek közül az A-csoportú streptococcusok által okozott fertőzés kiemelendő. A jelenlegi irányelvek alapján nem ajánlott rutinszerű, preventív antibiotikumkezelés az A-csoportú streptococcusok által okozott szövődmények megelőzésére. Célkitűzés: Célunk volt meghatározni, hogy a lepedékes tonsillitis miatt felvett gyermekek esetén jelenthet-e differenciáldiagnosztikai segítséget a laboratóriumi értékek változása a felesleges antibiotikumhasználat elkerülésében. Módszer: A vizsgálat során 133 beteg 135, exsudativ tonsillitis miatt történt megjelenésének adatait elemeztük. A betegeket két csoportba osztottuk. Az 1. csoportba kerültek azok a betegek, akiknél EBV vagy CMV kóroki szerepe volt igazolható, míg a 2. csoportba azokat a betegeket soroltuk, akiknél szerológiai módszerekkel nem volt igazolható vírusfertőzés. Eredmények: A vizsgálati eredmények alapján 2016 és 2017 között az exsudativ tonsillitisek többségénél (66/135, 48,8%) a CMV és az EBV kóroki szerepe volt igazolható szerológiai módszerrel, míg Streptococcus pyogenes jelenléte csak néhány esetben (3/65, 4,61%) volt kimutatható torokváladékból. A betegek jelentős, 92%-a a fentiek ellenére antibiotikumkezelésben részesült. Következtetés: Retrospektív felmérésünk eredményei is alátámasztották, hogy a klinikai tünetek és a fizikális status alapján nem lehetséges a kóroki tényezőt megítélni, sőt a legtöbb esetben a kvalitatív vérkép eltérései és a gyulladásos markerek – például a C-reaktív protein (CRP) – emelkedése sem jelez egyértelműen bakteriális infekciót. Ellenben a transzaminázértékek emelkedése magas pozitív prediktív értékkel utal vírusfertőzésre, azon belül is a vizsgálat tárgyát képező CMV- és EBV-infekcióra. A laborvizsgálatok ez irányú kiterjesztésével a felesleges antibiotikumhasználat jelentősen csökkenthető. Orv Hetil. 2020; 161(2): 50–55.

Published
2020
Full Text
View/download PDF

4. [Exudative tonsillitis in children

Author

Andrea, Takács, Dániel, Szűcs, and Gabriella, Terhes

Subjects
Tonsillitis, Virus Diseases, Streptococcal Infections, Humans, Pharynx, Bacterial Infections, Antibodies, Viral, Child, Antibodies, Bacterial, Anti-Bacterial Agents, Retrospective Studies
Abstract

Absztrakt

Published
2020

5. Gyulladásos bélbetegségben szenvedő gyermekek kezelésének átadása felnőttszakrendelésre. 10 éves tapasztalataink összegzése

Author

Tamás Molnár, A. Várkonyi, Anna Fábián, Ágnes Milassin, Noémi Vass, Dániel Szűcs, Renáta Bor, Mariann Rutka, Kata Szántó, Zoltán Szepes, Anita Bálint, Ferenc Nagy, and Klaudia Farkas

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Medical record, General Medicine, Disease, Adult care, medicine.disease, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, medicine, 030211 gastroenterology & hepatology, Transitional care, business, Patient transfer, Paediatric care, Paediatric patients
Abstract

Abstract: Introduction: Transfer is a planned movement of patients and their medical records from one provider to another. Only a few data are available from real life in inflammatory bowel disease patients in this topic. Aim: Our aim was to retrospectively evaluate the results of the transfer of our patients without longitudinal transition. Method: Data of the transferred patients at the University of Szeged were analysed. Patients were diagnosed in paediatric care. Transfer strategy at our departments was detailed medical summary. Results: 59 patients were enrolled in this study. 28.8% of the patients had mild to moderate disease activity and 71.2% was in remission at the time of transfer. Steroid therapy was initiated in 58% of the patients within an average of 9.1 months after the transfer. Anti-tumor necrosis factor therapy was given to 24% of the patients during the paediatric care and to an additional 23% in the adult care within an average of 28 months. Almost 70% of the patients received immunosuppressive therapy during paediatric and adult care. Surgery was required in 17% of the patients within an average 10.7 months after the transfer. Conclusion: Our results revealed that one-third of the paediatric patients have been transferred to adult care in active stage of disease. Shortly after the transfer 58% of the patients required corticosteroids and 17% surgery. Every fifth patient needed biological therapy to be initiated after the transfer. Longitudinal transition may have a potential to decrease the need for therapeutic change and the relatively high rate of surgery. Orv Hetil. 2018; 159(44): 1789–1793.

Published
2018
Full Text
View/download PDF

6. Laparoscopic-Assisted Percutaneous Endoscopic Gastrostomy Reduces Major Complications in High-Risk Pediatric Patients

Author

Brigitta Balogh, Anna Rieth, Gabriella Gavallér, Tamás Kovács, and Dániel Szűcs

Subjects
medicine.medical_specialty, Complications, Percutaneous, medicine.medical_treatment, Perforation (oil well), macromolecular substances, 03 medical and health sciences, 0302 clinical medicine, Pneumoperitoneum, 030225 pediatrics, Percutaneous endoscopic gastrostomy, Deformity, medicine, Child, Laparoscopy, Gastrostomy, Hepatology, medicine.diagnostic_test, business.industry, technology, industry, and agriculture, Gastroenterology, medicine.disease, Surgery, Pediatrics, Perinatology and Child Health, Original Article, 030211 gastroenterology & hepatology, medicine.symptom, business, Abdominal surgery
Abstract

Purpose Percutaneous endoscopic gastrostomy (PEG) is a safe method to feed patients with feeding difficulty. This study aimed to compare the outcomes of conventional PEG and laparoscopic-assisted PEG (L-PEG) placement in high-risk pediatric patients. Methods In our tertiary pediatric department, 90 PEG insertions were performed between 2014 and 2019. Children with severe thoracoabdominal deformity (TAD), previous abdominal surgery, ventriculoperitoneal (VP) shunt, and abdominal tumors were considered as high-risk patients. Age, sex, diagnosis, operative time, complications, and mortality were compared among patients who underwent conventional PEG placement (first group) and those who underwent L-PEG placement (second group). Results We analyzed the outcomes of conventional PEG placement (first group, n=15; patients with severe TAD [n=7], abdominal tumor [n=6], and VP shunts [n=2]) and L-PEG placement (second group, n=10; patients with VP shunts [n=5], previous abdominal surgery [n=4], and severe TAD [n=1]). Regarding minor complications, 1 (6.6%) patient in the first group underwent unplanned PEG removal and 1 (10%) patient in the second group had peristomal granuloma. We observed three major complications: colon perforation (6.6%) in a patient with VP shunt, gastrocolic fistula (6.6%) in a patient with Fallot-tetralogy and severe TAD, and pneumoperitoneum (6.6%) caused by early tube dislodgement in an autistic patient with severe TAD. All the three complications occurred in the first group (20%). No major complications occurred in the second group. Conclusion In high-risk patients, L-PEG may be safer than conventional PEG. Thus, L-PEG is recommended for high-risk patients.

Published
2021
Full Text
View/download PDF

7. Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease

Author

András Kiss, Gábor Veres, Dániel Szűcs, Dorottya Kocsis, Zoltán Kiss, Ádám Vannay, Nóra Judit Béres, András Arató, Dolóresz Szabó, Erna Sziksz, Katalin Eszter Müller, Attila Szabo, and Gábor Lendvai

Subjects
Male, 0301 basic medicine, Pathology, medicine.medical_specialty, Adolescent, Real-Time Polymerase Chain Reaction, Inflammatory bowel disease, miR-155, 03 medical and health sciences, HT29 Cells, Crohn Disease, medicine, Humans, Immunology and Allergy, RNA, Messenger, Child, Crohn's disease, Reverse Transcriptase Polymerase Chain Reaction, Tumor Necrosis Factor-alpha, business.industry, Gastroenterology, Prognosis, medicine.disease, Ulcerative colitis, digestive system diseases, Reverse transcription polymerase chain reaction, MicroRNAs, 030104 developmental biology, Real-time polymerase chain reaction, Case-Control Studies, Colitis, Ulcerative, Female, Tumor necrosis factor alpha, business, Follow-Up Studies
Abstract

BACKGROUND Evidence suggests the central role of tumor necrosis factor (TNF)-α in the pathomechanism of inflammatory bowel disease (IBD); however, its effect on epigenetic factors, including small non-coding microRNAs (miRs), is less known. Our present aim was the comparative investigation of the expression of TNF-α and immune response-related miRs in children with Crohn's disease (CD) and ulcerative colitis (UC). METHODS Fresh-frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) biopsies were used to analyze the expression of miR-146a, -155, -122, and TNF-α by real-time reverse transcription polymerase chain reaction in macroscopically inflamed (CD: 12 FFPE and 24 FF; UC: 10 FF) and intact (CD: 12 FFPE; 14 FF) colonic biopsies of children with IBD and controls (16 FFPE; 23 FF). The expression of miR-146a, -155, and -122 was also determined in TNF-α-treated HT-29 colonic epithelial cells. RESULTS Increased expression of TNF-α was observed in the colonic mucosa of children with CD and UC in comparison with controls. Expression of miR-146a and -155 was higher in the inflamed mucosa of children with CD and UC than in the intact mucosa. Expression of miR-122 elevated in the macroscopically intact colonic regions of CD compared with controls and patients with UC. In HT-29 cells, TNF-α treatment increased the expression of miR-146a and -155, but not that of miR-122. CONCLUSIONS Our results showed altered expression of miR-146a, -155, and -122 in the colonic mucosa of children with IBD and in TNF-α-treated colonic epithelial cells. Our data suggest the TNF-α-related involvement of these miRs in the pathogenesis of IBD.

Published
2016
Full Text
View/download PDF

8. [Transfer of care of adolescent inflammatory bowel disease patients without longitudinal transition. Lesson from 10 years experiences]

Author

Kata, Szántó, Dániel, Szűcs, Noémi, Vass, Ágnes, Várkonyi, Anita, Bálint, Renáta, Bor, Anna, Fábián, Ágnes, Milassin, Mariann, Rutka, Zoltán, Szepes, Ferenc, Nagy, Tamás, Molnár, and Klaudia, Farkas

Subjects
Male, Hungary, Transition to Adult Care, Time Factors, Adolescent, Adolescent Medicine, Patient Handoff, Humans, Female, Interdisciplinary Communication, Inflammatory Bowel Diseases, Referral and Consultation
Abstract

Transfer is a planned movement of patients and their medical records from one provider to another. Only a few data are available from real life in inflammatory bowel disease patients in this topic.Our aim was to retrospectively evaluate the results of the transfer of our patients without longitudinal transition.Data of the transferred patients at the University of Szeged were analysed. Patients were diagnosed in paediatric care. Transfer strategy at our departments was detailed medical summary.59 patients were enrolled in this study. 28.8% of the patients had mild to moderate disease activity and 71.2% was in remission at the time of transfer. Steroid therapy was initiated in 58% of the patients within an average of 9.1 months after the transfer. Anti-tumor necrosis factor therapy was given to 24% of the patients during the paediatric care and to an additional 23% in the adult care within an average of 28 months. Almost 70% of the patients received immunosuppressive therapy during paediatric and adult care. Surgery was required in 17% of the patients within an average 10.7 months after the transfer.Our results revealed that one-third of the paediatric patients have been transferred to adult care in active stage of disease. Shortly after the transfer 58% of the patients required corticosteroids and 17% surgery. Every fifth patient needed biological therapy to be initiated after the transfer. Longitudinal transition may have a potential to decrease the need for therapeutic change and the relatively high rate of surgery. Orv Hetil. 2018; 159(44): 1789-1793.Absztrakt: Bevezetés: A gyulladásos bélbetegségek gyakran serdülőkorban manifesztálódnak. A transzfer a betegek gyermekgyógyászati szakrendelésről történő átadását kísérő folyamatnak, a tranzíciónak az utolsó lépése, melynek kimenetelével ez idáig kisszámú tanulmány foglalkozott. Célkitűzés: Felmérni az általunk alkalmazott transzfer eredményességét gyermekszakrendelésről felnőttszakrendelésre átkerülő betegeink körében. Módszer: A Szegedi Tudományegyetem, I. Belgyógyászati Klinikára átkerült és gondozott betegek demográfiai és klinikai adatait elemeztük retrospektív módon. Az általunk vizsgált betegeknél a gyulladásos bélbetegség diagnózisa a gyermekgyógyászati ellátásban került felállításra. Klinikánkon a betegek transzferje során részletes egészségügyi dokumentáció elkészítése és átadása történt. Eredmények: 59 gyulladásos bélbeteg adatait elemeztük. Huszonhét esetben (45,7%) történt endoszkópia a transzferhez kötötten. A transzfer idejében a betegek 28,8%-ánál enyhe, illetve közepesen súlyos volt a betegség aktivitása, míg 71,2%-uk remisszióban volt. A betegek 58%-ánál kortikoszteroid indult, átlagosan 9,1 hónap után. Anti-tumornekrózisfaktor-terápia a gyermekgyógyászati ellátás alatt a betegek 24%-ánál lett bevezetve, és a betegek további 23%-ánál történt meg a felnőttellátás során, a transzfert követően átlagosan 28 hónapon belül. A betegek 70%-a részesült immunszuppresszív kezelésben a transzfer körüli időszakban. Sebészeti beavatkozásra 17%-ban volt szükség a transzfer után átlagosan 10,7 hónapon belül. Következtetés: Betegeink egyharmada aktív állapotban került át a felnőttellátásba. Fiatal betegeink 58%-a igényelt kortikoszteroidterápiát és 17%-a sebészeti beavatkozást a transzfert követő kevesebb, mint egy éven belül. Minden ötödik betegnél biológiai terápia indult a felnőttellátásban. A longitudinális tranzíció folyamatát alkalmazva valószínűleg volna esélyünk csökkenteni az átadásközeli terápiaeszkalációk számát és a relatíve magas sebészeti beavatkozási arányt. Orv Hetil. 2018; 159(44): 1789–1793.

Published
2018

9. Measurement of gastric-to-end-tidal carbon dioxide difference in neonates requiring intensive care

Author

Domokos Boda, Dániel Szűcs, Márta Katona, Ágnes Király, Gyula Tálosi, and Orsolya Szakál

Subjects
Critical Care, Manometry, Critical Illness, Neonatal age, Infant, Newborn, Diseases, chemistry.chemical_compound, Capnography, Intensive Care Units, Neonatal, Intensive care, Tidal Volume, Birth Weight, Humans, Medicine, Prospective cohort study, Gastric tonometry, business.industry, Stomach, Infant, Newborn, Obstetrics and Gynecology, Carbon Dioxide, Respiration, Artificial, chemistry, Gastric Mucosa, Anesthesia, Pediatrics, Perinatology and Child Health, Carbon dioxide, Analysis of variance, Splanchnic, business, Perfusion
Abstract

Gastric-arterial partial CO(2) pressure gap (P(g-)(a)CO(2) gap) measured by gastric tonometry may detect the disturbance of splanchnic perfusion. As in the neonatal age it is very difficult to follow up the circulatory condition with frequent acid-base examinations, we wanted to compare the P(g-)(a)CO(2) gap with an alternative gap of P(g)CO(2) - end-tidal carbon dioxide (P(g)(-)(ET)CO(2) gap).A prospective study was performed on ventilated neonates requiring intensive therapy (n = 44, weight: 1813 ± 977 g). P(ET)CO(2) and P(g)CO(2) were measured with a side stream capnograph. We applied a newly developed gastric tonometric probe. Patients were divided into two groups: Group 1 of patients in stable condition (n = 35) and Group 2 of patients with severe condition (i.e. Clinical Risk Index for Babies [CRIB] score higher than 10; n = 9). For main statistical analysis a mixed model repeated measurements ANOVA, Bland-Altman analysis were applied.P(g)(-)(ET)CO(2) gap was higher than P(g-)(a)CO(2) gap (11.40 ± 7.79 versus 3.63 ± 7.98 mmHg, p0.01). Both gaps were higher in Group 2 (8.71 ± 10.89 and 18.27 ± 10.49 versus 2.53 ± 6.78 and 9.92 ± 6.22 mmHg, p0.01 and p0.05). Bland-Altman analysis of the two gaps showed an acceptable correspondence.P(g)(-)(ET)CO(2) gap may be used as a method for continuous estimation of splanchnic perfusion and a prognostic index also in critically ill neonates. However, the P(g-)(a)CO(2) gap should not be abandoned.

Published
2012
Full Text
View/download PDF

10. P628 Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiences

Author

Anna Fábián, Ferenc Nagy, Noémi Vass, Zoltán Szepes, Kata Szántó, Renáta Bor, T Molnár, Dániel Szűcs, Klaudia Farkas, Mariann Rutka, Ágnes Milassin, and Anita Bálint

Subjects
medicine.medical_specialty, business.industry, Transition (fiction), Family medicine, Gastroenterology, Medicine, General Medicine, business, Transfer of care
Published
2018
Full Text
View/download PDF

11. Seasonal variability of vitamin D and bone metabolism in infliximab-treated paediatric Crohn's disease

Author

András Arató, Attila Szabo, Peter L. Lakatos, Antal Dezsőfi, Dolóresz Szabó, Gábor Veres, Dániel Szűcs, Mária Papp, Éva Hosszú, Nóra Judit Béres, and Katalin Eszter Müller

Subjects
musculoskeletal diseases, Vitamin, Male, medicine.medical_specialty, Pathology, Adolescent, Osteocalcin, Klinikai orvostudományok, Gastroenterology, Severity of Illness Index, Bone and Bones, Bone remodeling, chemistry.chemical_compound, Crohn Disease, Gastrointestinal Agents, Bone Density, Internal medicine, medicine, Vitamin D and neurology, Homeostasis, Humans, Prospective Studies, Vitamin D, skin and connective tissue diseases, Prospective cohort study, Child, Bone mineral, Crohn's disease, Hepatology, biology, business.industry, Orvostudományok, medicine.disease, Infliximab, chemistry, biology.protein, Female, Seasons, business, medicine.drug
Abstract

Paediatric Crohn's disease patients suffer from several complications, including low bone mineral density and inadequate serum levels of 25-hydroxy vitamin D.The aim of this prospective study was to address the effect of infliximab therapy on bone metabolism, bone mineral density and vitamin D homeostasis. The seasonal variability of serum vitamin D levels in relation to infliximab treatment was also analysed.Serum osteocalcin and beta-crosslaps (markers of bone metabolism), seasonal variability of vitamin D, and bone mineral density were assessed and followed throughout the yearlong treatment regimen of infliximab in 50 consecutive paediatric patients with moderate to severe Crohn's disease.Bone forming osteocalcin levels were significantly (p0.001) increased during infliximab therapy. In contrast, no significant changes in beta-crosslaps and vitamin D levels were observed. Vitamin D levels were significantly different when the summer and winter periods were compared at week 0 (p=0.039); however, this difference was not detected after one year of infliximab therapy. Despite the beneficial clinical effect of infliximab, there was no significant change in bone mineral density Z-scores after one year of treatment.Infliximab may beneficially affect bone homeostasis. Moreover, seasonal variability in vitamin D levels observed prior to initiation of infliximab treatment was diminished after one year of treatment.

Published
2015

12. Treatment of acutepancreatitis in a prospectively collected pediatric cohort

Author

Csilla Andorka, Dániel Szűcs, Anna Tóth, Ibolya Vass, Gábor Veres, Anita Demcsák, Ildikó Guthy, Balázs Németh, Dóra Mosztbacher, Noémi Vass, Csaba Bereczki, Veronika Ila, István Tokodi, Andrea Párniczky, Hegyi Péter, Judit Czelecz, Erika Tomsits, András Tárnok, Natália Lásztity, Gergely Tóth, László Gárdos, and Andrea Szentesi

Subjects
Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Cohort, Gastroenterology, medicine, business
Published
2016
Full Text
View/download PDF

13. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease

Author

Eva Micskey, Piroska Bodi, Marianne Polgár, István Tokodi, Gábor Veres, Ildikó Guthy, Áron Cseh, Mária Papp, András Tárnok, Dániel Szűcs, András Arató, László Gárdos, Enikő Sólyom, Noémi Vass, Judit B. Kovács, Erzsébet Szakos, Katalin Eszter Müller, Agnes Horvath, Gergely Tóth, Márta Kovács, Péter Vörös, M Balogh, Noémi Csoszánszki, Peter L. Lakatos, Dolóresz Szabó, A. Várkonyi, Antal Dezsőfi, and Éva Nemes

Subjects
Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Klinikai orvostudományok, Gastroenterology, Inflammatory bowel disease, Severity of Illness Index, Cohort Studies, Crohn Disease, Adrenal Cortex Hormones, Internal medicine, medicine, Humans, Prospective Studies, Registries, Practice Patterns, Physicians', Prospective cohort study, Child, Pediatric gastroenterology, Hungary, business.industry, Incidence (epidemiology), Incidence, Anti-Inflammatory Agents, Non-Steroidal, Bowel resection, Orvostudományok, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, Child, Preschool, Pediatrics, Perinatology and Child Health, Cohort, Disease Progression, Colitis, Ulcerative, Female, business, Immunosuppressive Agents, Cohort study, Follow-Up Studies
Abstract

OBJECTIVES The aim of the study was to evaluate the incidence, baseline disease characteristics, and disease location based on the Paris classification in pediatric inflammatory bowel disease (IBD) in the Hungarian nationwide inception cohort. In addition, 1-year follow-up with therapy was analyzed. METHODS From January 1, 2007 to December 31, 2009, newly diagnosed pediatric patients with IBD were prospectively registered. Twenty-seven pediatric gastroenterology centers participated in the data collection ensuring the data from the whole country. Newly diagnosed patients with IBD younger than 18 years were reported. Disease location was classified according to the Paris classification. RESULTS A total of 420 patients were identified. The incidence rate of pediatric IBD was 7.48/10⁵ (95% confidence interval [CI] 6.34/10⁵-8.83/10⁵). The incidence for Crohn disease (CD) was 4.72/10⁵ (95% CI 3.82-5.79), for ulcerative colitis (UC) 2.32/10⁵ (95% CI 1.71-3.09), and for IBD-unclassified 0.45/10⁵ (95% CI 0.22-0.84). Most common location in CD was L3 (58.7%); typical upper gastrointestinal abnormalities (ulcer, erosion and aphthous lesion) were observed in 29.9%. Extensive colitis in patients with UC (E4, proximal to hepatic flexure) was the most common disease phenotype (57%), whereas only 5% of children had proctitis. A total of 18.6% of patients had ever severe disease (S1). Frequency of azathioprine administration at diagnosis was 29.5% in patients with CD, and this rate increased to 54.6% (130/238) at 1-year follow-up. In UC, only 3.3% received azathioprine initially, and this rate elevated to 22.5% (25/111). Use of corticosteroid decreased from 50% to 15.3% in patients with UC. Rate of bowel resection in patients with CD during the first year of follow-up was 5%. CONCLUSIONS The incidence of pediatric IBD in Hungary was among the higher range reported. This is the first large, nationwide incident cohort analyzed according to the Paris classification, which is a useful tool to determine the characteristic pediatric CD phenotype.

Published
2013

14. Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of 68Ga-, 205/206Bi-, and 177Lu-Labeled NAPamide-Based Radiopharmaceuticals

Author

Dániel Szücs, Judit P. Szabó, Viktória Arató, Barbara Gyuricza, Dezső Szikra, Imre Tóth, Zita Képes, György Trencsényi, and Anikó Fekete

Subjects
albumin-binding moiety, malignant melanoma (MM), melanocortin-1 receptor (MC1-R), NAPamide, positron emission tomography (PET), radiolabeling, Medicine, Pharmacy and materia medica, RS1-441
Abstract

Although radiolabeled alpha-melanocyte stimulating hormone-analogue NAPamide derivatives are valuable melanoma-specific diagnostic probes, their rapid elimination kinetics and high renal uptake may preclude them from being used in clinical settings. We aimed at improving the pharmacokinetics of radiolabeled DOTA-NAPamide compounds by incorporating a 4-(p-iodo-phenyl)-butanoic acid (IPB) into the molecules. Followed by 68Ga-, 205/206Bi-, and 177Lu-labelling, the radiopharmaceuticals ([68Ga]Ga-DOTA-IPB-NAPamide, [205/206Bi]Bi-DOTA-IPB-NAPamide, [177Lu]Lu-DOTA-IPB-NAPamide) were characterized in vitro. To test the imaging behavior of the IPB-containing probes, B16F10 tumor-bearing C57BL/6 mice were subjected to in vivo microPET/microSPECT/CT imaging and ex vivo biodistribution studies. All tracers were stable in vitro, with radiochemical purity exceeding 98%. The use of albumin-binding moiety lengthened the in vivo biological half-life of the IPB-carrying radiopharmaceuticals, resulting in elevated tumor accumulation. Both [68Ga]Ga-DOTA-IPB-NAPamide (5.06 ± 1.08 %ID/g) and [205/206Bi]Bi-DOTA-IPB-NAPamide (4.50 ± 0.98 %ID/g) exhibited higher B16F10 tumor concentrations than their matches without the albumin-binding residue ([68Ga]Ga-DOTA-NAPamide and [205/206Bi]Bi-DOTA-NAPamide: 1.18 ± 0.27 %ID/g and 3.14 ± 0.32; respectively), however; the large amounts of off-target radioactivity do not confirm the benefits of half-life extension for short-lived isotopes. Enhanced [177Lu]Lu-DOTA-IPB-NAPamide tumor uptake even 24 h post-injection proved the advantage of IPB-based prolonged circulation time regarding long-lived radionuclides, although the significant background noise must be addressed in this case as well.

Published
2023
Full Text
View/download PDF

15. Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease

Author

Attila Szabo, Réka Rokonay, Csaba Bereczki, Erna Sziksz, Kriszta Katinka Boros, Ádám Vannay, Zoltán Kiss, Gábor Veres, Dániel Szűcs, Katalin Borka, András Arató, and Nóra Judit Béres

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Adolescent, Duodenum, In Vitro Techniques, Real-Time Polymerase Chain Reaction, Inflammatory bowel disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Intestinal mucosa, Transforming Growth Factor beta, Internal medicine, medicine, Humans, Intestinal Mucosa, Child, Fibroblast, Crohn's disease, biology, Reverse Transcriptase Polymerase Chain Reaction, business.industry, Epithelial Cells, General Medicine, Transforming growth factor beta, Fibroblasts, Basic Study, medicine.disease, MicroRNAs, 030104 developmental biology, medicine.anatomical_structure, Real-time polymerase chain reaction, biology.protein, Female, 030211 gastroenterology & hepatology, business, Transforming growth factor
Abstract

AIM: To evaluate the role of microRNA (miR)-146a, -155 and -122 in the duodenal mucosa of pediatric patients with Crohn’s disease (CD) and the effect of transforming growth factor-β (TGF-β) on these miRs in duodenal epithelial and fibroblast cells. METHODS: Formalin-fixed, paraffin-embedded biopsies derived from the macroscopically inflamed (CD inflamed: n = 10) and intact (CD intact: n = 10) duodenal mucosa of pediatric CD patients and control children (C: n = 10) were examined. Expression of miR-146a, -155 and -122 was determined by real-time polymerase-chain reaction (PCR). The expression of the above miRs was investigated in recombinant human TGF-β (1 nmol/L, 24 h) or vehicle treated small intestinal epithelial cells (CCL-241) and primary duodenal fibroblast cells derived from healthy children as well. RESULTS: Expression of miR-146a was significantly higher in the inflamed duodenal mucosa compared to the intact duodenal mucosa of children with CD (CD inflamed: 3.21 ± 0.50 vs CD intact: 0.62 ± 0.26, P ≤ 0.01) and to the control group (CD inflamed: 3.21 ± 0.50 vs C: 1.00 ± 0.33, P ≤ 0.05). The expression of miR-155 was significantly increased in the inflamed region of the duodenum compared to the control group (CD inflamed: 4.87 ± 1.02 vs Control: 1.00 ± 0.40, P ≤ 0.001). The expression of miR-122 was unchanged in the inflamed or intact mucosa of CD patients compared to controls. TGF-β treatment significantly decreased the expression of miR-155 in small intestinal epithelial cells (TGF-β: 0.7 ± 0.083 vs Control: 1 ± 0.09, P ≤ 0.05) and also the expression of miR-146a (TGF-β: 0.67 ± 0.04 vs Control: 1 ± 0.15, P ≤ 0.01) and miR-155 (TGF-β: 0.72 ± 0.09 vs Control: 1 ± 0.06, P ≤ 0.05) in primary duodenal fibroblasts compared to corresponding vehicle treated controls. TGF-β treatment did not influence the expression of miR-122. CONCLUSION: The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease. Anti-inflammatory TGF-β plays an important role in the regulation of the expression of these miRs.

Published
2016
Full Text
View/download PDF

16. Pediatric pancreatitis. Multicentre prospective data collection and analysis by the Hungarian Pancreatic Study Group

Author

Judit Czelecz, Anna Tóth, Péter Hegyi, Gábor Veres, Balázs Németh, Richárd Szmola, Miklós Sahin-Tóth, Csilla Andorka, Dániel Szűcs, Ildikó Guthy, Andrea Párniczky, Natália Lásztity, Noémi Vass, Dóra Mosztbacher, and Anita Balázs

Subjects
medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Internal medicine, Gastroenterology, Prospective data, Medicine, Pancreatitis, business, Intensive care medicine, medicine.disease
Published
2015
Full Text
View/download PDF

17. Therapeutic Performance Evaluation of 213Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([213Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology

Author

Zita Képes, Viktória Arató, Judit P. Szabó, Barbara Gyuricza, Dániel Szücs, István Hajdu, Anikó Fekete, Frank Bruchertseifer, Dezső Szikra, and György Trencsényi

Subjects
APN/CD13 (Aminopeptidase N), [213Bi]Bi-DOTAGA-cKNGRE, fibrosarcoma, HT1080, NGR (asparagine-glycine-arginine), positron emission tomography (PET), Pharmacy and materia medica, RS1-441
Abstract

Since NGR-tripeptides (asparagine-glycine-arginine) selectively target neoangiogenesis-associated Aminopeptidase N (APN/CD13) on cancer cells, we aimed to evaluate the in vivo tumour targeting capability of radiolabelled, NGR-containing, ANP/CD13-selective [213Bi]Bi-DOTAGA-cKNGRE in CD13pos. HT1080 fibrosarcoma-bearing severe combined immunodeficient CB17 mice. 10 ± 1 days after cancer cell inoculation, positron emission tomography (PET) was performed applying [68Ga]Ga-DOTAGA-cKNGRE for tumour verification. On the 7th, 8th, 10th and 12th days the treated group of tumourous mice were intraperitoneally administered with 4.68 ± 0.10 MBq [213Bi]Bi-DOTAGA-cKNGRE, while the untreated tumour-bearing animals received 150 μL saline solution. In addition to body weight (BW) and tumour volume measurements, ex vivo biodistribution studies were conducted 30 and 90 min postinjection (pi.). The following quantitative standardised uptake values (SUV) confirmed the detectability of the HT1080 tumours: SUVmean and SUVmax: 0.37 ± 0.09 and 0.86 ± 0.14, respectively. Although no significant difference (p ≤ 0.05) was encountered between the BW of the treated and untreated mice, their tumour volumes measured on the 9th, 10th and 12th days differed significantly (p ≤ 0.01). Relatively higher [213Bi]Bi-DOTAGA-cKNGRE accumulation of the HT1080 neoplasms (%ID/g: 0.80 ± 0.16) compared with the other organs at 90 min time point yields better tumour-to-background ratios. Therefore, the therapeutic application of APN/CD13-affine [213Bi]Bi-DOTAGA- cKNGRE seems to be promising in receptor-positive fibrosarcoma treatment.

Published
2023
Full Text
View/download PDF

18. The Synthesis and Preclinical Investigation of Lactosamine-Based Radiopharmaceuticals for the Detection of Galectin-3-Expressing Melanoma Cells

Author

Barbara Gyuricza, Ágnes Szűcs, Judit P. Szabó, Viktória Arató, Zita Képes, Dániel Szücs, Dezső Szikra, György Trencsényi, and Anikó Fekete

Subjects
galectin-3, radiolabeling, radiopharmaceutical, PET imaging, Pharmacy and materia medica, RS1-441
Abstract

Given that galectin-3 (Gal-3) is a β-galactoside-binding lectin promoting tumor growth and metastatis, it could be a valuable target for the treatment of Gal-3-expressing neoplasms. An aromatic group introduced to the C-3′ position of lactosamine increased its affinity for Gal-3. Herein, we aimed at developing a radiopharmaceutical for the detection of Gal-3 positive malignancies. To enhance tumor specificity, a heterodimeric radiotracer capable of binding to both Gal-3 and αvβ3 integrin was also synthetized. Arginine-glycine-asparagine (RGD) peptide is the ligand of angiogenesis- and metastasis-associated αvβ3 integrin. Following the synthesis of the chelator-conjugated (2-naphthyl)methylated lactosamine, the obtained compound was applied as a precursor for radiolabeling and was conjugated to the RGD peptide by click reaction as well. Both synthetized precursors were radiolabeled with 68Ga, resulting in high labeling yield (>97). The biological studies were carried out using B16F10 melanoma tumor-bearing C57BL6 mice. High tumor accumulation of both labeled lactosamine derivatives—detected by in vivo PET and ex vivo biodistribution studies—indicated their potential for melanoma detection. However, the heterodimer radiotracer showed high hepatic uptake, while low liver accumulation characterized chelator-conjugated lactosamine, resulting in PET images with excellent contrast. Therefore, this novel carbohydrate-based radiotracer is suitable for the highly selective determination of Gal-3-expressing melanoma cells.

Published
2022
Full Text
View/download PDF

19. Synthesis, Physicochemical, Labeling and In Vivo Characterization of 44Sc-Labeled DO3AM-NI as a Hypoxia-Sensitive PET Probe

Author

Dániel Szücs, Tibor Csupász, Judit P. Szabó, Adrienn Kis, Barbara Gyuricza, Viktória Arató, Viktória Forgács, Adrienn Vágner, Gábor Nagy, Ildikó Garai, Dezső Szikra, Imre Tóth, György Trencsényi, Gyula Tircsó, and Anikó Fekete

Subjects
radiopharmaceutical, physicochemical study, scandium-44, radiochemistry, positron emission tomography, tumor hypoxia, Medicine, Pharmacy and materia medica, RS1-441
Abstract

Hypoxia promotes angiogenesis, which is crucial for tumor growth, and induces malignant progression and increases the therapeutic resistance. Positron emission tomography (PET) enables the detection of the hypoxic regions in tumors using 2-nitroimidazole-based radiopharmaceuticals. We describe here a physicochemical study of the Sc(DO3AM-NI) complex, which indicates: (a) relatively slow formation of the Sc(DO3AM-NI) chelate in acidic solution; (b) lower thermodynamic stability than the reference Sc(DOTA); (c) however, it is substantially more inert and consequently can be regarded as an excellent Sc-binder system. In addition, we report a comparison of 44Sc-labeled DO3AM-NI with its known 68Ga-labeled analog as a hypoxia PET probe. The in vivo and ex vivo biodistributions of 44Sc- and 68Ga-labeled DO3AM-NI in healthy and KB tumor-bearing SCID mice were examined 90 and 240 min after intravenous injection. No significant difference was found between the accumulation of 44Sc- and 68Ga-labeled DO3AM-NI in KB tumors. However, a significantly higher accumulation of [68Ga]Ga(DO3AM-NI) was found in liver, spleen, kidney, intestine, lung, heart and brain than for [44Sc]Sc(DO3AM-NI), leading to a lower tumor/background ratio. The tumor-to-muscle (T/M) ratio of [44Sc]Sc(DO3AM-NI) was approximately 10–15-fold higher than that of [68Ga]Ga(DO3AM-NI) at all time points. Thus, [44Sc]Sc(DO3AM-NI) allows the visualization of KB tumors with higher resolution, making it a promising hypoxia-specific PET radiotracer.

Published
2022
Full Text
View/download PDF

20. A New Oxygen Containing Pyclen-Type Ligand as a Manganese(II) Binder for MRI and 52Mn PET Applications: Equilibrium, Kinetic, Relaxometric, Structural and Radiochemical Studies

Author

Tibor Csupász, Dániel Szücs, Ferenc Krisztián Kálmán, Oldamur Hollóczki, Anikó Fekete, Dezső Szikra, Éva Tóth, Imre Tóth, and Gyula Tircsó

Subjects
manganese, magnetic resonance imaging, contrast agents, macrocycles, stability, dissociation kinetics, Organic chemistry, QD241-441
Abstract

A new pyclen-3,9-diacetate derivative ligand (H23,9-OPC2A) was synthesized possessing an etheric O-atom opposite to the pyridine ring, to improve the dissociation kinetics of its Mn(II) complex (pyclen = 3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene). The new ligand is less basic than the N-containing analogue (H23,9-PC2A) due to the non-protonable O-atom. In spite of its lower basicity, the conditional stability of the [Mn(3,9-OPC2A)] (pMn = −log(Mn(II)), cL = cMn(II) = 0.01 mM. pH = 7.4) remains unaffected (pMn = 8.69), compared to the [Mn(3,9-PC2A)] (pMn = 8.64). The [Mn(3,9-OPC2A)] possesses one water molecule, having a lower exchange rate with bulk solvents (kex298 = 5.3 ± 0.4 × 107 s−1) than [Mn(3,9-PC2A)] (kex298 = 1.26 × 108 s−1). These mild differences are rationalized by density-functional theory (DFT) calculations. The acid assisted dissociation of [Mn(3,9-OPC2A)] is considerably slower (k1 = 2.81 ± 0.07 M−1 s−1) than that of the complexes of diacetates or bisamides of various 12-membered macrocycles and the parent H23,9-PC2A. The [Mn(3,9-OPC2A)] is inert in rat/human serum as confirmed by 52Mn labeling (nM range), as well as by relaxometry (mM range). However, a 600-fold excess of EDTA (pH = 7.4) or a mixture of essential metal ions, propagated some transchelation/transmetalation in 7 days. The H23,9-OPC2A is labeled efficiently with 52Mn at elevated temperatures, yet at 37 °C the parent H23,9-PC2A performs slightly better. Ultimately, the H23,9-OPC2A shows advantageous features for further ligand designs for bifunctional chelators.

Published
2022
Full Text
View/download PDF

21. Methods for the Determination of Transition Metal Impurities in Cyclotron-Produced Radiometals

Author

Viktória Forgács, Anikó Fekete, Barbara Gyuricza, Dániel Szücs, György Trencsényi, and Dezső Szikra

Subjects
radiometal, gallium-68, high-performance liquid chromatography, 4-(2-pyridylazo)resorcinol, xylenol orange, transition metal ions, Medicine, Pharmacy and materia medica, RS1-441
Abstract

Cyclotron-produced radiometals must be separated from the irradiated target and purified from other metal impurities, which could interfere with the radiolabeling process. We compared different chromatographic and colorimetric methods to determine the amount of transition metals in radioactive samples. Besides commercially available colorimetric tests, 4-(2-pyridylazo)resorcinol and xylenol orange were used as a non-selective metal reagents, forming water-soluble chelates with most of the transition metals immediately. We compared the applicability of pre- and post-column derivatization, as well as colorimetric determination without separation. The studied chromatographic and colorimetric analyses are not suitable to completely replace atomic spectroscopic techniques for the determination of metal contaminants in radioactive samples, but they may play an important role in the development of methods for the purification of radiometals and in their routine quality control.

Published
2022
Full Text
View/download PDF

22. Synthesis of 68Ga-Labeled cNGR-Based Glycopeptides and In Vivo Evaluation by PET Imaging

Author

Barbara Gyuricza, Judit P. Szabó, Viktória Arató, Noémi Dénes, Ágnes Szűcs, Katalin Berta, Adrienn Kis, Dániel Szücs, Viktória Forgács, Dezső Szikra, István Kertész, György Trencsényi, and Anikó Fekete

Subjects
radiopharmaceuticals, gallium-68, positron emission tomography (PET), aminopeptidase N receptor (APN/CD13), NGR peptide, Pharmacy and materia medica, RS1-441
Abstract

Tumor hypoxia induces angiogenesis, which is required for tumor cell survival. The aminopeptidase N receptor (APN/CD13) is an excellent marker of angiogenesis since it is overexpressed in angiogenic blood vessels and in tumor cells. Asparagine-glycine-arginine (NGR) peptide analogs bind selectively to the APN/CD13 recepto, therefore, they are important vector molecules in the development of a PET radiotracer which is capable of detecting APN-rich tumors. To investigate the effect of glycosylation and pegylation on in-vivo efficacy of an NGR-based radiotracer, two 68Ga-labeled radioglycopeptides were synthesized. A lactosamine derivative was applied to glycosylation of the NGR derivative and PEG4 moiety was used for pegylation. The receptor targeting potential and biodistribution of the radiopeptides were evaluated with in vivo PET imaging studies and ex vivo tissue distribution studies using B16-F10 melanoma tumor-bearing mice. According to these studies, all synthesized radiopeptides were capable of detecting APN expression in B16-F10 melanoma tumor. In addition, lower hepatic uptake, higher tumor-to background (T/M) ratio and prolonged circulation time were observed for the novel [68Ga]-10 radiotracer due to pegylation and glycosylation, resulting in more contrasting PET imaging. These in vivo PET imaging results correlated well with the ex vivo tissue distribution data.

Published
2021
Full Text
View/download PDF

23. Synthesis of Novel, Dual-Targeting 68Ga-NODAGA-LacN-E[c(RGDfK)]2 Glycopeptide as a PET Imaging Agent for Cancer Diagnosis

Author

Barbara Gyuricza, Judit P. Szabó, Viktória Arató, Dániel Szücs, Adrienn Vágner, Dezső Szikra, and Anikó Fekete

Subjects
radiopharmaceuticals, positron emission tomography (PET), αvβ3 integrin, RGD peptide, gallium-68, radiochemistry, Pharmacy and materia medica, RS1-441
Abstract

Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to αvβ3 integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer cell lines, therefore, it is an excellent biomarker for cancer diagnosis. The galectin-3 protein is also highly expressed in tumor cells and N-acetyllactosamine is a well-established ligand of this receptor. We have developed a synthetic method to prepare a lactosamine-containing radiotracer, namely 68Ga-NODAGA-LacN-E[c(RGDfK)]2, for cancer diagnosis. First, a lactosamine derivative with azido-propyl aglycone was synthetized. Then, NODAGA-NHS was attached to the amino group of this lactosamine derivative. The obtained compound was conjugated to an E[c(RGDfK)]2 peptide with a strain-promoted click reaction. We have accomplished the radiolabeling of the synthetized NODAGA-LacN-E[c(RGDfK)]2 precursor with a positron-emitting 68Ga isotope (radiochemical yield of >95%). The purification of the labeled compound with solid-phase extraction resulted in a radiochemical purity of >99%. Subsequently, the octanol–water partition coefficient (log P) of the labeled complex was determined to be −2.58. In addition, the in vitro stability of 68Ga-NODAGA-LacN-E[c(RGDfK)]2 was investigated and it was found that it was stable under the examined conditions.

Published
2021
Full Text
View/download PDF

24. Increased duodenal expression of miR-146a and -155 in pediatric Crohn's disease.

Author

Szűcs D, Béres NJ, Rokonay R, Boros K, Borka K, Kiss Z, Arató A, Szabó AJ, Vannay Á, Sziksz E, Bereczki C, and Veres G

Subjects
Adolescent, Child, Crohn Disease metabolism, Duodenum cytology, Duodenum drug effects, Epithelial Cells drug effects, Epithelial Cells metabolism, Female, Fibroblasts drug effects, Fibroblasts metabolism, Humans, In Vitro Techniques, Intestinal Mucosa cytology, Intestinal Mucosa drug effects, Male, MicroRNAs drug effects, MicroRNAs metabolism, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Transforming Growth Factor beta pharmacology, Crohn Disease genetics, Duodenum metabolism, Intestinal Mucosa metabolism, MicroRNAs genetics
Abstract

Aim: To evaluate the role of microRNA (miR)-146a, -155 and -122 in the duodenal mucosa of pediatric patients with Crohn's disease (CD) and the effect of transforming growth factor-β (TGF-β) on these miRs in duodenal epithelial and fibroblast cells., Methods: Formalin-fixed, paraffin-embedded biopsies derived from the macroscopically inflamed (CD inflamed: n = 10) and intact (CD intact: n = 10) duodenal mucosa of pediatric CD patients and control children (C: n = 10) were examined. Expression of miR-146a, -155 and -122 was determined by real-time polymerase-chain reaction (PCR). The expression of the above miRs was investigated in recombinant human TGF-β (1 nmol/L, 24 h) or vehicle treated small intestinal epithelial cells (CCL-241) and primary duodenal fibroblast cells derived from healthy children as well., Results: Expression of miR-146a was significantly higher in the inflamed duodenal mucosa compared to the intact duodenal mucosa of children with CD (CD inflamed: 3.21 ± 0.50 vs CD intact: 0.62 ± 0.26, P ≤ 0.01) and to the control group (CD inflamed: 3.21 ± 0.50 vs C: 1.00 ± 0.33, P ≤ 0.05). The expression of miR-155 was significantly increased in the inflamed region of the duodenum compared to the control group (CD inflamed: 4.87 ± 1.02 vs, Control: 1.00 ± 0.40, P ≤ 0.001). The expression of miR-122 was unchanged in the inflamed or intact mucosa of CD patients compared to controls. TGF-β treatment significantly decreased the expression of miR-155 in small intestinal epithelial cells (TGF-β: 0.7 ± 0.083 vs, Control: 1 ± 0.09, P ≤ 0.05) and also the expression of miR-146a (TGF-β: 0.67 ± 0.04 vs, Control: 1 ± 0.15, P ≤ 0.01) and miR-155 (TGF-β: 0.72 ± 0.09 vs, Control: 1 ± 0.06, P ≤ 0.05) in primary duodenal fibroblasts compared to corresponding vehicle treated controls. TGF-β treatment did not influence the expression of miR-122., Conclusion: The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease. Anti-inflammatory TGF-β plays an important role in the regulation of the expression of these miRs.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results